Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity.

Chimeric antigen receptor T cells (CART) targeting lymphocyte antigens can induce T cell fratricide and require additional engineering to mitigate self-damage. We demonstrate that the expression of a chimeric antigen receptor (CAR) targeting CD5, a prominent pan-T cell antigen, induces rapid internalization and complete loss of the CD5 protein on T cells, protecting them from self-targeting. Notably, exposure of healthy and malignant T cells to CD5.

CAR T Cells in T Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.

Chimeric antigen receptor (CAR T) therapy produced excellent activity in patients with relapsed/refractory B-lineage malignancies. However, extending these therapies to T cell cancers requires overcoming unique challenges. In the recent years, multiple approaches have been developed in preclinical models and some were tested in clinical trials in patients with treatment-refractory T-cell malignanices with promising early results.

[Effectiveness of chronic periodontal disease treatment by infrared laser light].

Thirty-six patients with light and moderate chronic periodontal disease (CPD) were included in the study. The patients were divided in two groups according to treatment options: first group (18 patients) received conventional periodontal treatment, second (18 patients) - in addition to conventional treatment were treated by phototherapy (infrared laser light). Control group included 10 persons with no signs of periodontal disease.

Cushing's syndrome: still a potential killing disease.

When Harvey Cushing described his syndrome in 1932 he named it the killing disease because of its cardiovascular complications. Heart failure is rarely reported as a presenting feature. We report a case in which left ventricular failure (LVF) was the predominant feature, associated with gross left ventricular hypertrophy (LVH) which regressed after treatment.